Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

Feng, Jiao; Dai, Weiqi; Mao, Yuqing; Wu, Liwei; Li, Jingjing; Chen, Kan; Yu, Qiang; Kong, Rui; Li, Sainan; Zhang, Jie; Ji, Jie; Wu, Jianye; Mo, Wenhui; Xu, Xuanfu; Guo, Chuanyong

doi:10.1186/s13046-020-1528-x

Public

Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

Published in Journal of Experimental & Clinical Cancer Research • Jan 30, 2020

Authors:

Jiao Feng

Weiqi Dai

Yuqing Mao

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a common primary malignant tumor which usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a first line medicine for advanced stage HCC; however, it has been faced with enormous resistance. Simvastatin (Sim) is a choles...

Subject

Sorafenib

Hepatocellular carcinoma

PKM2

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!